Amarin Corp Plc (AMRN)

[KCSVEN]

Non Generic Lovaza are such low #'s its meaningless.

It would be interesting to get a breakdown of % of Vascepa to % of Generic Lovaza among Cardiologist as compared to non-cardiologist.


It's education and insurance(overall cost) and the "hey, it works for you so far, why switch." Once expanded label it won't matter as there will be Vascepa in that expanded label area and no competitor.

If every statin prescription written was matched with a corresponding Vascepa subscription annual revenue could be around $34 billion.